By blocking these inhibitory signals, ICIs restore T-cell activation and promote antitumor immunity.PD-1 inhibitors, such as tislelizumab, nivolumab, and pembrolizumab, specifically target the PD-1 receptor on T cells, preventing its interaction with PD-L1 expressed on tumor cells and immune-suppressive cells (3). Here, CD274 is linked to neoplasm.